GlycoNex Incorporation (TPEX:4168)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
29.40
+0.80 (2.80%)
Jan 21, 2026, 1:30 PM CST
23.01%
Market Cap3.18B
Revenue (ttm)36.63M
Net Income (ttm)-217.59M
Shares Out108.21M
EPS (ttm)-2.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,092,291
Average Volume663,578
Open28.40
Previous Close28.60
Day's Range28.00 - 30.00
52-Week Range15.60 - 30.95
Beta0.55
RSI72.27
Earnings DateMar 13, 2026

About GlycoNex Incorporation

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company’s development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed antibody drug currently under the lead optimization stage; and GNX1021, a first-in-class antibody–drug conjugate currently under preclinical stage. It is a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4168
Full Company Profile

Financial Performance

In 2024, GlycoNex Incorporation's revenue was 14.70 million, an increase of 478.32% compared to the previous year's 2.54 million. Losses were -229.71 million, 28.8% more than in 2023.

Financial Statements